Pipeline

Vizz (LENZ Therapeutics) is the first and only aceclidine-based eye drop for presbyopia and is also the first daily solution to correct vision for up to 10 hours.

EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD.

Santen introduces low-dose atropine in Germany, marking a significant advancement in myopia management for children amid a global epidemic.

New research reveals collagen mimetic peptides may effectively restore ocular tissue stiffness, offering hope for myopia and other eye diseases.

A Prescription Drug User Fee Act (PDUFA) target action date of December 16, 2025, was assigned by the FDA.

The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation.

Acuvue Oasys MAX 1-Day multifocal for astigmatism is the first and only daily disposable multifocal toric contact lens.

Lifitegrast 5.0% significantly improves clinical signs and biomarkers in dry eye disease, demonstrating effective results within 12 weeks of treatment.

Johnson & Johnson introduces Acuvue Oasys MAX 1-Day multifocal toric lenses, the first and only daily disposable contact lens for astigmatism and presbyopia.

This new QLS-111 and latanoprost fixed-dose combination (QLS-111-FDC; Qlaris) is in development for the treatment of primary open-angle glaucoma, ocular hypertension, and normal-tension glaucoma in patients whose optimal intraocular pressure control may remain “unachievable” due to needing to lower episcleral venous pressure.

At the 2025 ASCRS meeting, Mitch Shultz, MD, presented compelling new findings from a 12-week clinical trial investigating the impact of lotilaner 0.25% ophthalmic solution on meibomian gland function.

IVMED-85 is a preservative-free, nonatropine daily drop that slows myopia progression by strengthening scleral and corneal collagen crosslinks via LOX activation.

The PDUFA date for Brimochol PF is January 28, 2026.

The investigators described the CASIA2 (Tomey Corporation) instrument, which is a new AS-OCT device with a swept-source laser wavelength of 1310 nm that can scan at a speed of 50,000 A-scan/second.

Alcon’s dry eye candidate acoltremon 0.003% is a first-in-class thermoreceptor agonist, which stimulates corneal sensory nerves to increase natural tear production to treat the signs and symptoms of dry eye disease.

New data from North American and Chinese clinical trials reinforce the safety, efficacy, and durability of DOT lenses in slowing pediatric myopia progression, without evidence of rebound.

NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop with a dual mechanism of action (nitric oxide and prostaglandin analogue).

Topline results from the MAGNIFY phase 2 clinical trial of oral zervimesine show 28.6% slower geographic atrophy lesion growth compared with placebo.

Boehringer Ingelheim announced that the phase 2 clinical studies will investigate a potential first-in-class oral compound and a highly specific antibody fragment for geographic atrophy.

Insurance coverage from the second largest health plan in the US paves the way for expanded access to Luminopia’s unique amblyopia therapeutic.

New data for 0.25% reproxalap was announced by Aldeyra Therapeutics, supporting the company’s NDA resubmission for the treatment of dry eye disease.

Dilsher Dhoot, MD, FASRS, shares his forward-looking perspective on developments in retinal disease management, highlighting both recent breakthroughs and promising innovations on the horizon.

Results from the first-in-human study of SpyGlass Pharma's bimatoprost-eluting IOL showed significant reduction in IOP and improved best-corrected distance visual acuity.

According to a press release, Myatro XL is the first 0.05% atropine eye drop for pediatric myopia control. It will be commercially available in India in July 2025.

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.

Leos is supported by emerging data from a randomized controlled clinical trial, further validating its safety and efficacy.

The supplemental BLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion and for broadening the dosing schedule to include every-4-week dosing across approved indications.